Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
J Natl Cancer Inst
    January 2018
  1. MARISA L, Svrcek M, Collura A, Becht E, et al
    The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    J Natl Cancer Inst. 2018;110.
    >> Share

  2. MLECNIK B, Van den Eynde M, Bindea G, Church SE, et al
    Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
    J Natl Cancer Inst. 2018;110.
    >> Share

  3. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    >> Share

  4. HANLEY CJ, Mellone M, Ford K, Thirdborough SM, et al
    Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
    J Natl Cancer Inst. 2018;110.
    >> Share

    December 2017
  5. SJOQUIST KM, Renfro LA, Simes RJ, Tebbutt NC, et al
    Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
    J Natl Cancer Inst. 2017 Dec 18. pii: 4757465. doi: 10.1093.
    >> Share

  6. FOKAS E, Strobel P, Fietkau R, Ghadimi M, et al
    Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

    September 2017
  7. RUERS T, Van Coevorden F, Punt CJ, Pierie JE, et al
    Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    J Natl Cancer Inst. 2017;109.
    >> Share

    August 2017
  8. UBINK I, Elias SG, Moelans CB, Lacle MM, et al
    A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.
    J Natl Cancer Inst. 2017;109.
    >> Share

  9. SIEGEL RL, Fedewa SA, Anderson WF, Miller KD, et al
    Colorectal Cancer Incidence Patterns in the United States, 1974-2013.
    J Natl Cancer Inst. 2017;109.
    >> Share

  10. ZHANG L, Shay JW
    Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  11. MURPHY CC, Sanoff HK, Stitzenberg KB, Baron JA, et al
    RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.
    J Natl Cancer Inst. 2017;109.
    >> Share

  12. MOLENAAR RJ, Radivoyevitch T, Wilmink JW
    RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.
    J Natl Cancer Inst. 2017;109.
    >> Share

    July 2017
  13. SELIGMANN JF, Seymour MT
    Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime.
    J Natl Cancer Inst. 2017;109.
    >> Share

    May 2017
  14. TAIEB J, Le Malicot K, Shi Q, Penault Lorca F, et al
    Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  15. GUPTA S, Nodora J
    Optimizing the Quality of the Colorectal Cancer Screening Continuum: A Call to Action.
    J Natl Cancer Inst. 2017;109.
    >> Share

  16. LEE YC, Li-Sheng Chen S, Ming-Fang Yen A, Yueh-Hsia Chiu S, et al
    Association Between Colorectal Cancer Mortality and Gradient Fecal Hemoglobin Concentration in Colonoscopy Noncompliers.
    J Natl Cancer Inst. 2017;109.
    >> Share

    February 2017
  17. PICCO G, Petti C, Sassi F, Grillone K, et al
    Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  18. PICCO G, Petti C, Sassi F, Grillone K, et al
    Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
    J Natl Cancer Inst. 2017;109:1-12.
    >> Share

    January 2017
  19. IMPERIALE TF, Yu M, Monahan PO, Stump TE, et al
    Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool.
    J Natl Cancer Inst. 2016;109.
    >> Share

  20. GEBLER C, Lohoff T, Paszkowski-Rogacz M, Mircetic J, et al
    Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.
    J Natl Cancer Inst. 2016;109.
    >> Share

    September 2016
  21. OSUGA T, Takimoto R, Ono M, Hirakawa M, et al
    Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

    August 2016
  22. FERRIS RL, Galon J
    Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification.
    J Natl Cancer Inst. 2016;108.
    >> Share

  23. ROZEK LS, Schmit SL, Greenson JK, Tomsho LP, et al
    Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

    June 2016
  24. SCHULTHEIS AM, Ng CK, De Filippo MR, Piscuoglio S, et al
    Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    J Natl Cancer Inst. 2016;108:djv427.
    >> Share

    April 2016
  25. ANTONUZZO L, Lunghi A, Giommoni E, Brugia M, et al
    Regorafenib Also Can Cause Osteonecrosis of the Jaw.
    J Natl Cancer Inst. 2016;108.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016